China · Delayed Price · Currency is CNY Hinova Pharmaceuticals Statistics
Total Valuation
SHA:688302 has a market cap or net worth of CNY 3.26 billion. The enterprise value is 2.58 billion.
| Market Cap | 3.26B |
| Enterprise Value | 2.58B |
Important Dates
The last earnings date was Thursday, August 27, 2026.
| Earnings Date | Aug 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SHA:688302 has 99.02 million shares outstanding. The number of shares has decreased by -1.26% in one year.
| Current Share Class | 99.02M |
| Shares Outstanding | 99.02M |
| Shares Change (YoY) | -1.26% |
| Shares Change (QoQ) | -1.96% |
| Owned by Insiders (%) | 20.16% |
| Owned by Institutions (%) | 18.17% |
| Float | 71.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 52.33 |
| PB Ratio | 3.23 |
| P/TBV Ratio | 3.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 41.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.17, with a Debt / Equity ratio of 0.10.
| Current Ratio | 6.17 |
| Quick Ratio | 5.76 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.64 |
| Interest Coverage | -1,073.53 |
Financial Efficiency
Return on equity (ROE) is -12.27% and return on invested capital (ROIC) is -8.46%.
| Return on Equity (ROE) | -12.27% |
| Return on Assets (ROA) | -7.48% |
| Return on Invested Capital (ROIC) | -8.46% |
| Return on Capital Employed (ROCE) | -14.06% |
| Weighted Average Cost of Capital (WACC) | 3.76% |
| Revenue Per Employee | 258,395 |
| Profits Per Employee | -546,131 |
| Employee Count | 241 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0.21 |
Taxes
In the past 12 months, SHA:688302 has paid 4,126 in taxes.
| Income Tax | 4,126 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.00% in the last 52 weeks. The beta is -0.07, so SHA:688302's price volatility has been lower than the market average.
| Beta (5Y) | -0.07 |
| 52-Week Price Change | -45.00% |
| 50-Day Moving Average | 36.19 |
| 200-Day Moving Average | 42.76 |
| Relative Strength Index (RSI) | 38.65 |
| Average Volume (20 Days) | 1,857,615 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SHA:688302 had revenue of CNY 62.27 million and -131.62 million in losses. Loss per share was -1.34.
| Revenue | 62.27M |
| Gross Profit | 60.59M |
| Operating Income | -159.52M |
| Pretax Income | -131.61M |
| Net Income | -131.62M |
| EBITDA | -153.52M |
| EBIT | -159.52M |
| Loss Per Share | -1.34 |
Balance Sheet
The company has 784.73 million in cash and 104.76 million in debt, with a net cash position of 679.96 million or 6.87 per share.
| Cash & Cash Equivalents | 784.73M |
| Total Debt | 104.76M |
| Net Cash | 679.96M |
| Net Cash Per Share | 6.87 |
| Equity (Book Value) | 1.01B |
| Book Value Per Share | 10.32 |
| Working Capital | 717.56M |
Cash Flow
In the last 12 months, operating cash flow was -107.84 million and capital expenditures -56.01 million, giving a free cash flow of -163.85 million.
| Operating Cash Flow | -107.84M |
| Capital Expenditures | -56.01M |
| Depreciation & Amortization | 6.00M |
| Net Borrowing | -1.67M |
| Free Cash Flow | -163.85M |
| FCF Per Share | -1.65 |
Margins
Gross margin is 97.30%, with operating and profit margins of -256.15% and -211.35%.
| Gross Margin | 97.30% |
| Operating Margin | -256.15% |
| Pretax Margin | -211.35% |
| Profit Margin | -211.35% |
| EBITDA Margin | -246.53% |
| EBIT Margin | -256.15% |
| FCF Margin | n/a |
Dividends & Yields
SHA:688302 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.26% |
| Shareholder Yield | 1.26% |
| Earnings Yield | -4.04% |
| FCF Yield | -5.03% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |